首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献,搜索用时 156 毫秒
1.
制备复合碱性成纤维细胞生长因子 (bFGF)可降解缓释微球 ,考察其生物活性的保存情况 ,以及它对成纤维细胞的作用。采用改良的乳化冷凝法交联制备复合bFGF的明胶缓释微球 ,将它加入成纤维细胞的培养液中 ,用细胞计数法、四甲基偶氮唑盐微量反应比色法 (MTT法 )测定细胞增殖情况。结果表明 ,复合bFGF的缓释微球平均粒径 12 .36± 3.5 6 μm ;培养 1d后各组细胞计数、吸光度 (A)值差异均无显著性 ;5d后 ,缓释微球组细胞计数、吸光度 (A)值明显高于对照组 ;7d后 ,缓释微球组值仍高于其它组 ,但差异无显著性。复合bFGF的缓释微球制备工艺简便 ,成球性好 ;能较长时间地持续释放活性bFGF ,明显促进成纤维细胞的增殖。  相似文献   

2.
背景:聚乳酸具有良好的生物相容性,是优良的药物缓释载体。目的:制备重组人骨形态发生蛋白2/聚乳酸缓释微球,考察其理化特性。方法:采用复乳溶剂挥发法制备重组人骨形态发生蛋白2/聚乳酸缓释微球,进行扫描电镜、激光粒度、Zeta电位、溶胀性能检测及采用ELISA试剂盒检测包封率、载药率及体外释药率。结果与结论:扫描电镜见重组人骨形态发生蛋白2/聚乳酸缓释微球微球近似圆形,形态较规则,分散性较好,表面光滑。激光粒度分析重组人骨形态发生蛋白2/聚乳酸缓释微球微平均粒径839.6 nm,Zeta电位(-32.93±3.74)mV,微球溶胀系数1.157±0.059,包封率及载药率分别为(88.943±2.878)%,(0.026±0.001)%;微球在第1天释药约10.199%,随后释药较恒定,至第19天累计释药率为54.643%。说明制备出的重组人骨形态发生蛋白2/聚乳酸缓释微球的粒径达到中华人民共和国药典第10版二部关于亚微球的定义标准及包封率不低于80%的要求,并且在体外具有很好的缓释功能。  相似文献   

3.
本研究旨在探讨甲基丙烯酸缩水甘油酯右旋糖酐(dex-GMA)载碱性成纤维细胞生长因子(bFGF)凝胶纳米微球(dex-GMA-bFGF-NPs)对骨髓间充质干细胞(BMSCs)生物学作用。采用改良乳液聚合技术合成纳米微球,将单纯bFGF(A组)、空白dex-GMA凝胶纳米微球(B组)和载bFGF凝胶纳米微球(C组)加入骨髓间充质干细胞培养液中,不添加任何添加物的单纯MSCs为空白对照组(D),用细胞计数法、噻唑蓝比色法(MTT法)、流式细胞术观察细胞增殖情况;并检测细胞ALP活性,以反映dex-GMA-bFGF-NPs对BMSCs分化情况的影响。结果显示:dex-GMA-bFGF-NPs大小均匀,包封率高达88%,85%的bFGF在前14 d释放。dex-GMA-bFGF-NPs对bFGF缓释有效促进BMSCs的增殖,在培养12 d后,A、B、C和D组细胞数分别为(21.97±0.25)×104个细胞/ml(、12.43±0.13)×104个细胞/ml(、27.45±0.78)×104个细胞/ml和(12.03±0.43)×104个细胞/ml,差异有统计学意义(P0.05),培养3 d后,A组的G2/M+S期百分数最高,7 d后,C组的G2/M+S期百分数最高。结论:dex-GMA-bFGF-NPs可控制活性bFGF的长时间持续释放,作为bFGF的缓释载体,可明显促进骨髓间充质干细胞的增殖和分化。  相似文献   

4.
背景:骨形态发生蛋白2可增加软骨细胞和祖细胞基质的产生,可增强组织金属蛋白酶抑制因子1、sox9基因、Ⅱ型胶原以及聚集蛋白聚糖的表达,具有诱导间充质细胞迁徙、增殖、分化,最终促使软骨、骨形成的作用。目的:制备重组人骨形态发生蛋白2聚羟基丁酸-羟基辛酸共聚酯纳米微球系统纳米微球缓释系统,观察微球生长因子形态和粒径分布、载药量、包封率、体外缓释时间及生物活性。方法:采用复乳-干燥法制备重组人骨形成蛋白2聚羟基丁酸-羟基辛酸共聚酯纳米微球系统,体外分离培养猪软骨细胞。实验分为3组:第1组培养液不添加药物做为对照;第2组培养液中添加含20μg/L重组人骨形态发生蛋白2;第3组培养液中添加20μg/L重组人骨形态发生蛋白2聚羟基丁酸-羟基辛酸共聚酯纳米微球系统纳米微球;其中在第2组和第3组又将重组人骨形态发生蛋白2和重组人骨形态发生蛋白2聚羟基丁酸-羟基辛酸共聚酯纳米微球系统纳米微球分别设为55,100μg/L两种的有效浓度,采用MTT法检测微球对软骨细胞增殖的影响,模拟体内条件观察纳米微球的体外缓释性及生物活性。结果与结论:该纳米微球表面光滑圆整,球体大小均匀,粒径为231-415 nm,扫描电镜平均粒径323 nm。微球的包封率和载药量分别为(79.63±0.16)%和(1.92±0.16)%。根据15 d内对重组人骨形态发生蛋白2聚羟基丁酸-羟基辛酸共聚酯纳米微球的体外释药的观察,保持持续释放重组人骨形态发生蛋白2,且释放的浓度呈增长水平。该微球缓释系统有生物活性,能显著促进猪软骨细胞的增殖,其效应高于单纯重组人骨形态发生蛋白2的效应。提示重组人骨形态发生蛋白2聚羟基丁酸-羟基辛酸共聚酯纳米微球缓释系统包封率、载药量、体外释药性以及生物活性符合纳米微球的一般规律,能够满足相应的软骨缺损修复要求。  相似文献   

5.
目的:制备复合碱性成纤维细胞生长因子的可降解缓释微球,考察其生物活性保存情况,以及其对上皮细胞的作用.方法:采用改良的乳化冷凝法交联制备明胶缓释微球,将其加入上皮细胞的培养液中,用细胞计数法、四甲基偶氮唑盐微量反应比色法(MTT法)测定细胞增殖情况.结果:缓释微球平均粒径(12.36±3.56)μm;培养1 d后各组细胞计数、吸光度(A)值差异均无显著性意义;5 d后,缓释微球组细胞计数、吸光度(A)值明显高于对照组;7 d后,缓释微球组值仍高于其它组,但差异无显著性意义.结论:复合生长因子的缓释微球制备工艺简便,成球性好;能较长时间持续释放活性生长因子,明显促进细胞增殖.  相似文献   

6.
背景:局部抗生素缓释系统可解决全身应用抗生素时引发的全毒性反应与短期局部注射抗生素半衰期短的问题。目的:制备盐酸万古霉素@聚乳酸-羟基乙酸共聚物-壳聚糖-透明质酸[vaneomyeinhydroehlorid@poly(lactic acid glycolic acid)-chitosanhyaluronic acid,VA@PLGA-CS-HA]复合缓释微球,并对其性能进行评价。方法:采用乳液法制备VA@PLGA-CS-HA复合缓释微球与未载药PLGA-CS-HA复合微球,其中载药微球中万古霉素的质量浓度分别为25,50,100 g/L,检测载药微球的载药量、包封率与体外缓释性能。将3种载药微球分别与金黄色葡萄球菌菌液共培养,相应时间点内检测抑菌率。将4种微球浸提液分别与MC3T3-E1细胞和MG-63细胞共培养,培养1,3,7 d后采用CCK-8法检测细胞毒性。结果与结论:(1)含盐酸万古霉素25,50,100 g/L载药微球的包封率分别为(79.70±5.11)%,(86.41±3.91)%,(63.18±1.96)%,载药量分别为(3.98±0.26)%,(8.64±0.39)%,(12.63±0.39)%;50 g/L载药微球的包封率高于100 g/L载药微球(P<0.05),100 g/L载药微球的载药量高于其他两组(P <0.05);(2)3种载药微球在24 h内均无明显的突释,其中50 g/L载药微球不同时间点的药物释放率快于其他两组,100 g/L载药微球不同时间点的药物释放量高于其他两组,并且3组在56 d时释放的药物质量浓度均高于盐酸万古霉素最小抗菌浓度;(3)3种载药微球均能在一定时间内有效杀死金黄色葡萄球菌,在第14-28天期间3种微球的相对菌落率低于3%,说明3种载药微球能持续而有效杀灭金黄色葡萄球菌;(4)含盐酸万古霉素25,50 g/L载药微球对MC3T3-E1细胞和MG-63细胞无明显的细胞毒性,100 g/L载药微球具有一定的细胞毒性;(5)结果表明,VA@PLGA-CS-HA微球具有良好的缓释性能、抗菌能力与生物组织相容性。  相似文献   

7.
制备壳聚糖微球体外缓释TGF-β1的研究   总被引:1,自引:0,他引:1  
应用离子交联沉淀法制备壳聚糖-转化生长因子(TGF-β1)缓释微球,研究其体外缓释性能。采用离子交联沉淀法制备壳聚糖微球,以其包裹TGF-β1,制备具有缓释效能的壳聚糖-TGF-β1缓释微球。用扫描电镜、激光粒度分析仪、Elisa法等观察其表面形态,测定药物载药率、包封率、体外缓释效率等指标。结果表明:所得微球球形良好,表面光滑,粒径分布集中,平均粒径272nm。壳聚糖微球有较高的药物包封率,达80.60%。体外释放试验提示,TGF-β1初期存在突释现象,前24h释放达27%,但其后可从壳聚糖微球中稳定释放,7d累计释放达41%。离子交联沉淀法制备壳聚糖缓释微球方法简单易行,所得壳聚糖-TGF-β1微球具有良好的缓释效能,提示其在组织工程领域具有良好的应用前景。  相似文献   

8.
应用离子交联沉淀法制备壳聚糖-转化生长因子(TGF-β1)缓释微球,研究其体外缓释性能。采用离子交联沉淀法制备壳聚糖微球,以其包裹TGF-β1,制备具有缓释效能的壳聚糖-TGF-β1缓释微球。用扫描电镜、激光粒度分析仪、Elisa法等观察其表面形态,测定药物载药率、包封率、体外缓释效率等指标。结果表明:所得微球球形良好,表面光滑,粒径分布集中,平均粒径272nm。壳聚糖微球有较高的药物包封率,达80.60%。体外释放试验提示,TGF-β1初期存在突释现象,前24h释放达27%,但其后可从壳聚糖微球中稳定释放,7d累计释放达41%。离子交联沉淀法制备壳聚糖缓释微球方法简单易行,所得壳聚糖-TGF-β1微球具有良好的缓释效能,提示其在组织工程领域具有良好的应用前景。  相似文献   

9.
目的制备出载硫酸长春新碱微球的胶原-壳聚糖缓释药膜,并考察该制剂的稳定性。方法采用W/O/O溶剂挥发法制备载硫酸长春新碱的聚乳酸/聚羟基乙酸共聚物(PLGA)微球,后把微球与壳聚糖、胶原溶液共混及二次冻干,制备出载硫酸长春新碱微球的胶原-壳聚糖药膜。对微球和药膜表面形态进行了电镜观察,测定了微球和药膜的包封率、载药量及药物释放,药物含量采用高效液相法检测。此外,还初步考察了缓释药膜的稳定性。结果制备的微球包封率达到79.0%±1.0%,微球药物的突释为27.2%±1.2%,制备成药膜后降低到18.0%±1.1%,采用该工艺流程制备出来的缓释药膜,药物突释明显减少。稳定性实验显示,该药膜在40℃条件下放置3个月药物含量下降到97.9%±0.1%,而高湿度或光照环境下放置10 d药物含量下降到91.4%±0.3%和91.2%±0.4%。结论药物包囊制成微球后与胶原、壳聚糖共混制备出的缓释药膜具有较好的释放特性和稳定性,有望成为一种实用的新型缓释抗肿瘤制剂。  相似文献   

10.
海藻酸盐控释微球的制备及其体外释药特性   总被引:1,自引:0,他引:1  
研制白蛋白海藻酸钠(BSA-海藻酸钙微球)控释微球,并对其体外释药特性等进行考察,为应力控释VEGF促进组织工程骨血管化提供理论依据。以海藻酸钠为载体,采用W/O乳化-离子交联法制备BSA-海藻酸钙微球;检测粒径大小、外观、包封率等理化特性;考察微球的体外释药特性。微球球形圆整,分散性好,平均粒径为230±60μm,载药量达80.3μg/mg,包封率为61%;微球的体外释药速率平稳,周期达2周余。海藻酸钠可以作为蛋白、多肽类药物的可生物降解辅料;乳化离子交联法的制备工艺简便,有利于蛋白、多肽类药物结构和功能的稳定性并有效延长其作用时间。  相似文献   

11.
The controlled release study of Vincristine Sulfate   总被引:2,自引:0,他引:2  
We prepared microspheres of Vincristine Sulfate (VCR) through drying-from-oil method, then mixed the microspheres into 0.7% collagen swelling solution to prepare emulsion, spread the emulsion on plate to form film by frozen-dry method. The film was cross-linked and sterilized, then planted into the site of tumor and expected to release at steady speed. We measured the release of VCR in vivo and in vitro by HPLC. The results demonstrated that VCR controlled release films release at approximate steady speed in 15 days.  相似文献   

12.
文题释义:基质细胞衍生因子1:是一种参与免疫细胞活化、分化和迁移及伤口愈合、角膜上皮再生和组织修复等过程的趋化因子,能促进干细胞的生长和发育,参与调节成骨分化,可通过细胞归巢提高干细胞向病灶区的趋化作用。而基质细胞衍生因子1的失活会损害成骨细胞的发育和分化。此外,其还与血管生成密切相关。 异烟肼:具有较高的杀菌活性,是治疗结核病的一线药物。世卫组织建议将异烟肼作为结核病的标准疗法,用于潜伏性结核病感染者的预防治疗,与利福平、吡嗪酰胺和乙胺丁醇一起用于治疗活动性肺结核。异烟肼的活化形式与脂肪酸生物合成Ⅱ型系统中的NADH依赖型烯醇酰基载体蛋白还原酶异烟肼a结合,阻断细菌细胞壁关键成分支原体酸的合成。 背景:抗结核化疗是目前治疗骨关节结核的主要手段,然而全身给药难以维持病灶区的有效浓度,治疗效果欠佳。 目的:制备一种原位、长期释放抗结核药物且兼备促成骨作用的壳聚糖-明胶/聚乳酸-羟基乙酸联合载药水凝胶。 方法:将亲水性的抗结核药物异烟肼和疏水性的基质细胞衍生因子通过复乳法负载到聚乳酸-羟基乙酸中,制备聚乳酸-羟基乙酸载药微球,共混至壳聚糖-明胶水凝胶支架中,制备壳聚糖-明胶/聚乳酸-羟基乙酸联合载药水凝胶。检测聚乳酸-羟基乙酸载药微球、壳聚糖-明胶/聚乳酸-羟基乙酸联合载药水凝胶的体外释药与抗结核杆菌的能力。将成骨前体细胞MC3T3-E1分别接种于载药微球与联合载药水凝胶表面,CCK-8法检测细胞活力,碱性磷酸酶活性检测细胞的成骨性能。 结果与结论:①载药微球中异烟肼1 h内的突释约为23.3%,2 d内的释放率约为42.6%,随后进入缓释期,25 d后进入平台期;基质细胞衍生因子1在1 h内的累积释放率约为19.8%,2 d内的释放率约为44.7%,随后进入缓释期,25 d后进入平台期;联合载药水凝胶中异烟肼和基质细胞衍生因子1最初1 h的释放分别为8.3%和8.5%,第2天的累计释放率分别为15.2%和17.6%,远低于聚乳酸-羟基乙酸微球;②体外4周后,联合载药水凝胶的抑菌直径大于载药微球,抑菌率高于载药微球(P < 0.05);③联合载药水凝胶与载药微球均具有良好的细胞相容性,细胞活力均约为100%;④培养5,10 d后,联合载药水凝胶表面的细胞碱性磷酸酶活性与载药微球比较差异无显著性意义(P > 0.05);⑤结果表明,原位壳聚糖-明胶/聚乳酸-羟基乙酸联合载药水凝胶有作为治疗骨关节结核及其他骨关节感染的潜力。 ORCID: 0000-0003-4166-2492(张贺龙) 中国组织工程研究杂志出版内容重点:生物材料;骨生物材料; 口腔生物材料; 纳米材料; 缓释材料; 材料相容性;组织工程  相似文献   

13.
Integration of a drug delivery function into implantable medical devices enables local release of specific bioactives to control cells-surface interactions. One alternative to achieve this biofunctionality for bone implants is to incorporate particulate drug delivery systems (DDSs) into the rough or porous implant surfaces. The scope of this study was to assess the effects of a model DDS consisting of poly(D,L-lactide-co-glycolide) (PLGA) microspheres loaded with an anti-inflammatory drug, dexamethasone (DXM), on the response of Simian Virus-immortalized Human Fetal Osteoblast (SV-HFO) cells. The microspheres were prepared by the oil-in-water emulsion/solvent evaporation method, whereas cells response was investigated by Alamar Blue test for viability, alkaline phosphatase (ALP) activity for differentiation, and Alizarin Red staining for matrix mineralization. Cell viability was not affected by the presence of increased concentrations of polymeric microspheres in the culture media. Furthermore, in the cultures with DXM-loaded microspheres, ALP activity was expressed at levels similar with those obtained under osteogenic conditions, indicating that DXM released from the microsphere-stimulated cell differentiation. Matrix mineralization occurred preferentially around the DXM-loaded microspheres confirming that the released DXM could act as osteogenic supplement for the cells. These in vitro findings suggest that a particulate PLGA-DXM DDS may actually provide dual, anti-inflammatory and osteogenic functions when incorporated on the surface of bone implants.  相似文献   

14.
Microspheres formulated from blending poly(lactide-co-glycolide) (PLGA) and poly(ethylene glycol)-grafted-chitosan (PEG-g-CHN), using a modified in-emulsion-solvent-evaporation method, were investigated for the delivery of protein. A model protein, bovine serum albumin (BSA), was incorporated into the PLGA/PEG-g-CHN microspheres and both initial burst and release kinetics could be modulated by varying the PEG-g-CHN content. Basic fibroblast growth factor (bFGF) was formulated into the microspheres containing 5% PEG-g-CHN and the bFGF contents in the releasates were determined by a receptor-based ELISA with their in vitro bioactivities validated by fibroblast cell culture. The in vivo effect of the bFGF microspheres formulation was evaluated in a hamster cheek pouch model using a 7 day exposure (e.g., before significant vascular remodeling was expected). Using intravital microscopy, the tissue showed no evidence of inflammation with any formulation; deliberate activation of a preconditioning response linked to inflammation was attenuated by BSA microspheres alone. Vasoactive responses (receptor-dependant and independent constriction and dilation) linked to nitric oxide were attenuated, and constriction to endothelin was enhanced in bFGF and not BSA containing microspheres. PLGA/PEG-g-CHN blended microspheres were also demonstrated to be non-inflammatory and non-thrombogenic in vivo by observing the vascular changes in the cheek pouch. In conclusion, the addition of PEG-g-CHN to PLGA microspheres can serve as a sustained delivery vehicle for bFGF and the released protein provides vasoactive changes consistent with chronic bFGF exposure.  相似文献   

15.
In this study, an oil-in-water emulsion solvent evaporation technique was used to fabricate poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV, 8% PHV), microspheres as scaffold, to guide liver cell growth. Human hepatoma cell lines, HepG2 and Hep3B, were cultured in vitro on both the microspheres and polymer films. SEM and optical microscope images showed that multilayer cells were formed among the microspheres to bridge them together and developed into cell-construct aggregates after 1 week of culture. MTT results showed that the cell proliferation on the microspheres was more than two times higher than that on the films after 12 days of culture. The cells seeded on microspheres secreted albumin 2-4 times more than that on the positive control after 1 week of culture, which indicated that this hepatic function was greatly improved by the aggregation of cells on microspheres. Although HepG2 failed to express P-450 activity, this hepatic function was preserved when Hep3B cultured on microspheres. All the results indicated that PHBV microspheres are appropriate scaffolds for liver tissue engineering.  相似文献   

16.
Optimal in vitro conditions are necessary for the development of a strong, well structured, and functional tissue engineered cardiovascular structure eventually designed for implantation. To further optimize in vitro conditions for cell proliferation and extracellular matrix formation in tissue engineering of cardiovascular structures, in this study, ascorbic acid and growth factors as additives to standard cell culture medium were evaluated for their effect on tissue development in vitro. Biodegradable polymer patches [polyglycolic acid (PGA) coated with poly-4-hydroxybutyrate (P4HB)] were seeded with human pediatric aortic cells and cultured for 7 and 28 days. Group A was cultured with standard medium (DMEM with 10% fetal calf serum and 1% antibiotics) supplemented with ascorbic acid; group B was cultured with standard medium plus ascorbic acid and basic fibroblast growth factor (bFGF); group C was cultured with standard medium adding ascorbic acid and transforming growth factor (TGF). Analysis of the cell seeded polymer constructs included DNA assay, collagen assay, and histologic and immunohistochemical examination for cell proliferation and collagen formation. After 7 and 28 days of culture, group B and group C showed a significantly higher DNA content compared with group A. The addition of bFGF (group B) led to a markedly higher collagen synthesis after 28 days of culture compared with the additives in groups C and A. The histologic and immunohistochemical examination also revealed a more dense, organized tissue development with pronounced matrix protein formation in the tissue engineered structures in group B after 28 days of culture. When seeded on to the polymeric scaffold, human vascular cells proliferate and form organized cell tissue after 28 days of culture. The addition of bFGF and ascorbic acid to the standard medium enhances cell proliferation and collagen synthesis on the biodegradable polymer, which leads to the formation of more mature, well organized tissue engineered structures.  相似文献   

17.
One the main problems of cancer chemotherapy is the unwanted damage to normal cells caused by the high toxicities of anticancer drugs. Any system of controlled drug delivery that would reduce the total amount of drug required, and thus reduce the side effects, would potentially help to improve chemotherapy. In this respect, biodegradable gelatin microspheres were prepared by water/oil emulsion polymerization and by crosslinking with glutaraldehyde (GTA) as the drug-carrier system. Microspheres were loaded with colchicine, a model antimitotic drug, which was frequently used as an antimitotic agent in cancer research involving cell cultures. Microsphere sizes, swelling and degradation properties, drug-release kinetics, and cytotoxities were studied. Swelling characteristics of microspheres changed upon changing GTA concentration. A decrease in swelling values was recorded as GTA crosslink density was increased. In vitro drug release in PBS (0.01M, pH 7.4) showed rapid colchicine release up to approximately 83% (at t = 92 h) for microspheres with low GTA (0.05% v/v), whereas a slower release profile (only approximately 39%) was obtained for microspheres with high GTA (0.50% v/v) content, for the same period. Cytotoxicity tests with MCF-7, HeLa and H-82 cancer cell lines showed that free colchicine was very toxic, showing an approximately 100% lethal effect in both HeLa and H-82 cell lines and more than 50% decrease in viability in MCF-7 cells in 4 days. Indeed, entrapped colchicine indicated similar initial high toxic effect on cell viability in MCF-7 cell line and this effect became more dominant as colchicine continued to be released from microspheres in the same period. In conclusion, the control of the release rate of colchicine from gelatin microspheres was achieved under in vitro conditions by gelatin through the alteration of crosslinking conditions. Indeed, the results suggested the potential application of gelatin microspheres crosslinked with GTA as a sustained drug-delivery system for anticancer drugs for local chemotherapy administrations.  相似文献   

18.
EGF和bFGF对成年大鼠神经干细胞增殖和分化的影响   总被引:4,自引:0,他引:4  
本研究旨在探索可促进成年大鼠神经干细胞增殖并形成较多的克隆球以及其分化出较多神经元的因素。取成鼠前脑室下区的组织进行原代培养 ,将之分为三组分别加入 EGF、b FGF以及 EGF+ b FGF,观察克隆球的形成状况。一周后收集三组原代细胞克隆球 ,加入完全培养液 (仅含 10 %胎牛血清 )进行分化实验。分化 14 d后 ,分别用 MAP-2和 GFAP的单克隆抗体进行免疫荧光标记 ,计算阳性细胞数量。无血清培养结果显示 ,b FGF组和 EGF+ b FGF组原代培养液中形成的原代克隆球数量和直径的差别不明显 ,但都明显地大于 EGF组。免疫荧光结果显示 ,b FGF组和 EGF+ b FGF组中的克隆球分化出 MAP-2阳性神经元的数量明显多于 EGF组 ,而 EGF组则能产生较多的胶质细胞。提示 ,b F GF能促进成年大鼠神经干细胞增殖 ,所形成的细胞克隆球能分化为较多的神经元。  相似文献   

19.
本研究观察了碱性成纤维生长因子对胚胎神经干细胞生长和分化的影响。从孕 12 d大鼠胚胎神经管分离神经干细胞 ,进行体外培养 ,分为碱性成纤维生长因子组及对照组。培养过程中观察神经干细胞的生长 ,于培养第 3、5、10 d用免疫组化方法检测培养细胞神经元特异烯醇化酶和胶质纤维酸性蛋白的表达 ,以观察神经干细胞分化为神经元及神经胶质细胞的状况。碱性成纤维生长因子可明显地促进培养细胞的生长和分化。免疫组化细胞计数显示 ,培养第 3 d,特异烯醇化酶、胶质纤维酸性蛋白阳性细胞数均明显增加 ;培养第 5 d,特异烯醇化酶阳性细胞数是对照组的 1.9倍 ,胶质纤维酸性蛋白阳性细胞数为对照组的 1.6倍 ,前者表达增加明显 ;培养第 10 d,两者的阳性细胞数仍高于对照组 ,但增加不明显。不同培养时间的胞体最长突起长度也均高于对照组 ;胞体直径及表面积随培养时间延长而增大。说明 ,碱性成纤维生长因子既能促进胚胎神经干细胞的生长 ,也可促使其分化为神经元及神经胶质细胞 ,尤以神经元为明显  相似文献   

20.
Vascularization into a poly(vinyl alcohol) (PVA) sponge was investigated using basic fibroblast growth factor (bFGF). This growth factor was impregnated into biodegradable gelatin microspheres for its sustained release and then the bFGF-containing microspheres or free bFGF were incorporated into PVA sponges. Following subcutaneous implantation into the back of mice, the bFGF-containing gelatin microspheres induced vascularization in and around the sponge to a significantly greater extent than that of free bFGF from 3 days after implantation. Significant ingrowth of fibrous tissue into the sponge was also observed when bFGF-containing microspheres were added to the sponge in contrast to free bFGF. Tissue ingrowth occurred into the deeper portion of the sponge over time while it accompanied formation of new capillaries. Empty gelatin microspheres had no effect on vascularization and the level of fibrous tissue ingrowth into the sponge was similar to that of the control group. It was concluded that incorporation of gelatin microspheres containing bFGF into the PVA sponge was effective in prevascularization of the sponge pores.  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号